top of page

Founder Mark Kotter describes the science that has enabled bit.bio to design and manufacture virtually any cell type and characteristic from iPSCs

  • blonca9
  • May 6, 2024
  • 1 min read

He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell type. The company is now using this to create cells for research purposes and as therapeutics.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page